Skip to content

Impact of Dietary Status on Vascular Function Before and After a Standardized Breakfast. An "Exposed/Unexposed" Study Embedded in the SUVIMAX2 Cohort

" Impact du Statut Alimentaire Sur la Fonction Vasculaire Avant et après un Petit-déjeuner standardisé. Une étude " exposé/Non exposé " nichée Dans la Cohorte SUVIMAX2

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01579409
Acronym
Nutri-MicroVas
Enrollment
94
Registered
2012-04-18
Start date
2011-11-01
Completion date
2014-03-04
Last updated
2026-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

French PNNS Guidelines in Vascular Function

Keywords

Nutrition, Arterial stiffness, Endothelial dysfunction, Microcirculation, Cardiac autonomic system.

Brief summary

In France, primary cardiovascular and metabolic prevention is supported by the French National Program for Nutrition and Health (PNNS: Programme National Nutrition Santé). The investigators made the hypothesis that, independently of other diseases, the non adherence in PNNS guidelines would lead to arterial stiffness, endothelial dysfunction, change in microcirculation and in cardiac autonomic system. These changes may exist at fasting but also be reinforced after a standardised breakfast. The investigators aim is to evaluate arterial stiffness, endothelial function, microcirculation and cardiac autonomic system according to PNNS status in a case control study.

Detailed description

This is a case / control pilot nested in SU.VI.MAX 2 (SUpplémentation en VItamines et Minéraux Anti-oXydants) study. The randomized longitudinal placebo controlled SU.VI.MAX study tested the preventive effect of vitamin and antioxidant minerals supplementation on the incidence and the mortality from cardiovascular pathologies and cancers. SU.VI.MAX 2 was the extension of the previous study and included 7200 subjects for whom food habits were known and characterized according to PNNS guidelines (PNNS score). The subjects will be pre-selected from the original cohort SU.VI.MAX2 if they have a PNNS score in 2007 in the 1-40th or 60-100th percentiles of distribution. If they accept to participate, a new PNNS score will be calculated in 2012-2013 and the subjects in the 1-25th or 75-100th percentiles will be included and explored during one day of participation. Our aim is to evaluate arterial stiffness, endothelial function, microcirculation and cardiac autonomic system according to PNNS status in a case control study. Our secondary objective is to evaluate the same parameters in the same subjects but after a breakfast containing 75 g glucose.

Interventions

DRUGPNNS guidelines

Application of PNNS guidelines

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Social Security affiliation. * Participation in SU.VI.MAX 2. * Subjects without legal guardian who can freely agree to participate to the study. * PNNS score in 2012 lower (cases) or upper (controls) quartile.

Exclusion criteria

* Known diabetes or prediabetes before the inclusion. * History of cardiovascular disease. * Treatment for hypertension. * Treatment for dyslipidemia. * Known Cancer * Smoking or patients that have stopped smoking less than 3 years * Cardiac pacemaker

Design outcomes

Primary

MeasureTime frameDescription
Pulse Wave VelocityDuring the fasting state, within the hour preceding the standardised breakfast that provides 75 gr of carbohydratesThis is a pilot study. Pulse wave velocity, an index of arterial stiffness, was chosen as the primary endpoint. A total of 47 subjects in each group was necessary to detect a difference between groups of 1m/s in pulse wave velocity (standard deviation of 1.7 m/s) with a statistical power of 80%, at fasting.
Peripheral arterial augmentation index (Aix )During the fasting state, within the hour preceding the standardised breakfast that provides 75 gr of carbohydrates
High and low frequency peaks in heart variability spectral analysisDuring the fasting state, within the hour preceding the standardised breakfast that provides 75 gr of carbohydrates
High and low frequency peaks in systolic and diastolic blood pressure spectral analysisDuring the fasting state, within the hour preceding the standardised breakfast that provides 75 gr of carbohydrates
Mean cutaneous blood flow measured by laser doppler flowmetryDuring the fasting state, within the hour preceding the standardised breakfast that provides 75 gr of carbohydrates
Mean cutaneous blood flow measured by laser doppler flowmetry, spectral analysisDuring the fasting state, within the hour preceding the standardised breakfast that provides 75 gr of carbohydrates
Percentage of variation of cutaneous blood flow laser doppler measurements after paced breathing (6/min)During the fasting state, within the hour preceding the standardised breakfast that provides 75 gr of carbohydrates
Increase in cutaneous blood flow laser doppler measurements after acetylcholine iontophoresisDuring the fasting state, within the hour preceding the standardised breakfast that provides 75 gr of carbohydrates
Reactive Hyperemia Index after branchial artery occlusionDuring the fasting state, within the hour preceding the standardised breakfast that provides 75 gr of carbohydrates
Aortic , radial,digital artery, systolic, diastolic and pulsatile pressuresDuring the fasting state, within the hour preceding the standardised breakfast that provides 75 gr of carbohydrates

Secondary

MeasureTime frame
Comparison of the above mentioned parameters after a standardised breakfastAfter the standardised breakfast that provides 75 gr of carbohydrates, hourly for the next 3 hours following the end of the standardised breakfast

Countries

France

Contacts

STUDY_DIRECTORPaul Valensi, MD

CNRH Ile de france

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 6, 2026